

**CLAIMS:**

1. (Currently amended) A method of affecting new neuron growth in a patient comprising the step of:

administering post ischemic event to a patient in need thereof a therapeutic amount of a therapeutic compound selected from the group of L-arginine, sildenafil, statins, and phosphodiesterase inhibitors for increasing levels of cGMP to a patient in need of neurogenesis ~~post-stroke~~ wherein increased levels of cGMP result in new neuron growth.

2-5. (Canceled)

6. (Currently amended) A method of augmenting the production of neurons in a patient by administering post ischemic event to a patient in need thereof an effective amount of a therapeutic compound selected from the group of L-arginine, sildenafil, statins, and phosphodiesterase inhibitors that increases levels of cGMP, to a site in need of augmentation, wherein increased levels of cGMP augment the production of new neurons.

7. (Currently amended) A method of increasing neurological function in a patient by administering post ischemic event to a patient in need thereof an effective amount of a therapeutic compound selected from the group of L-arginine, sildenafil, statins, and phosphodiesterase inhibitors that increases levels of cGMP to a patient in need of increased neurological function after neurological damage has occurred, whereby the increased levels of cGMP create new neuron growth, thereby increasing neurological function.

8. (Currently amended) A method of increasing cognitive and neurological function in a patient by administering post ischemic event an effective amount of a therapeutic compound selected from the group of L-arginine, sildenafil, statins, and phosphodiesterase inhibitors for increasing levels of cGMP to a patient in need of increased cognitive and neurological function after neurological and cognitive

damage has occurred, whereby the increased levels of cGMP create new neuron growth, thereby increasing neurological function.

9-13. (Canceled)